Q2 2020 Stryker Corp Earnings Call
KALAMAZOO Jul 31, 2020 (Thomson StreetEvents) -- Edited Transcript of Stryker Corp earnings conference call or presentation Thursday, July 30, 2020 at 8:30:00pm GMT
TEXT version of Transcript
* Glenn S. Boehnlein
Stryker Corporation - VP & CFO
* Kevin A. Lobo
Stryker Corporation - Chairman & CEO
* Preston Wells
Stryker Corporation - VP of IR
Conference Call Participants
* David Ryan Lewis
Morgan Stanley, Research Division - MD
* Frederick Allen Wise
Stifel, Nicolaus & Company, Incorporated, Research Division - MD & Senior Equity Research Analyst
* Joanne Karen Wuensch
Citigroup Inc., Research Division - MD
* Joshua Thomas Jennings
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst
* Kaila Paige Krum
SunTrust Robinson Humphrey, Inc., Research Division - Research Analyst
* Kristen Marie Stewart
Barclays Bank PLC, Research Division - Research Analyst
* Kyle William Rose
Canaccord Genuity Corp., Research Division - Senior Analyst
* Lawrence H. Biegelsen
Wells Fargo Securities, LLC, Research Division - Senior Medical Device Equity Research Analyst
* Matthew Stephan Miksic
Crdit Suisse AG, Research Division - Senior Research Analyst
* Patrick J. Bartoski
Piper Sandler & Co., Research Division - Research Analyst
* Richard S. Newitter
SVB Leerink LLC, Research Division - MD of Medical Supplies & Devices and Senior Research Analyst
* Robert Adam Hopkins
BofA Merrill Lynch, Research Division - MD of Equity Research
* Robert Justin Marcus
JPMorgan Chase & Co, Research Division - Analyst
* Ryan Benjamin Zimmerman
BTIG, LLC, Research Division - MD & Medical Technology Analyst
* Vijay Muniyappa Kumar
Evercore ISI Institutional Equities, Research Division - MD
* Xuyang Li
UBS Investment Bank, Research Division - Equity Research Analyst of Medical Supplies & Devices
Welcome to the Second Quarter 2020 Stryker Earnings Call. My name is Michelle, and I will be your operator for today's call. (Operator Instructions) This conference call is being recorded for replay purposes.
Before we begin, I would like to remind you that the discussions during this conference call will include forward-looking statements. Factors that could cause actual results to differ materially are discussed in the company's most recent filings with the SEC.
Also, the discussions will include certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP financial measures can be found in today's press release that is an exhibit to Stryker's current report on Form 8-K filed today with the SEC.
I will now turn the call over to Mr. Kevin Lobo, Chairman and Chief Executive Officer. You may proceed, sir.
Kevin A. Lobo, Stryker Corporation - Chairman & CEO 
Welcome to Stryker's second quarter earnings call. Joining me today are Glenn Boehnlein, Stryker's CFO; and Preston Wells, Vice President of Investor Relations. For today's call, I'll provide opening comments, followed by Preston with some perspectives on the recovery trends across our diverse businesses. Glenn will then provide additional details regarding our quarterly results before opening the call to Q&A.
As we begin today's call, I would like to start by thanking all our employees for their continued commitment to ensuring the safety of their colleagues, their families and our customers. I am very pleased with the resiliency of our organization, which has maintained high employee engagement and customer connections through the pandemic: from our sales forces, who have remained present and essential to the doctors and caregivers they support; to our manufacturing teams that have worked around the clock to optimize supply with ever-changing demand; and across our workforce, most of whom continue to collaborate virtually. The Stryker spirit remains alive and well.
Our second quarter sales declined organically by 24%, reflecting the impacts of COVID-19 across all geographies and the majority of our product lines. The results reflect progressive improvement in overall sales through the quarter but do vary by region. The sequential improvement can be tied to the initial cancellation and subsequent gradual return of elective procedures during the quarter.
As mentioned in our first quarter call, we took aggressive steps early on to ensure the safety of our employees and customers while managing discretionary spending across our P&L in response to the slowdown in sales. Our cost containment measures included significant reductions in travel and meetings, a slowdown in hiring and salary reductions across senior leaders. In addition, we made other efforts to focus on cash conservation, including the idling of select product lines and facilities across our network starting in May. These actions, combined with our sales performance resulted in adjusted earnings per share of $0.64, a decline of nearly 68% versus the prior year.
As we look at the quarter, the low point in sales occurred in April and then improved sequentially through the end of June. As a reminder, implants and disposables represent about 75% of our sales and small capital represents 16%. Small capital generally mirrors the performance and trends of implants and disposable. The largest improvements within the quarter were in hips, knees, spine, trauma, sports medicine and Neurotechnology, reflecting the resumption of elective procedures and the gradual opening of previously locked down communities and geographies.
With respect to our large capital businesses, medical capital and Mako were standouts, both posting strong growth for the quarter. Our Mako robotic technology remains in high demand with our customers despite any financial constraints resulting from the pandemic. By geography, Japan and Canada performed well, while Europe, China and Australia showed progressive improvement through the quarter. In contrast, Latin America and India continued to be weaker as the impacts of COVID-19 remain more widespread in those regions. In Q3, we expect the recovery to continue, but do not expect it to be linear while local governments deal with varying degrees of resurgences.
Our R&D programs continue to proceed despite logistical challenges caused by the pandemic, and we spent at a healthy rate in the quarter. We are actively engaging with our customers while ensuring that our product supply is in a strong position to capitalize as procedures resume. However, given the fluid nature of the situation, we are not providing Q3 or full year guidance. We are proceeding with the integration efforts regarding the right medical transaction. We are working cooperatively with the regulators to obtain the necessary approvals for the transaction, including, as previously announced, proposing to divest our STAR total ankle replacement product. This process is well underway, and the U.K. Competition and Markets Authority recently announced that it will consider our proposed undertakings in lieu of a Phase II investigation. We continue to expect to close the transaction around the end of Q3 or beginning of Q4.
Please note, beyond this update, we will not be taking any questions regarding Wright Medical or the pending transaction on today's call. This has been the most unique situation that most of us have ever experienced. While we have been impacted financially as a result of the government shutdowns and deferrals of elective procedures, this time has also allowed us opportunities to reevaluate and develop new ways to work and collaborate across our diverse group of businesses. We are prepared to emerge from the pandemic as stronger, more efficient company. I remain confident in our people, our culture and our ability to partner with our customers to meet the needs of the many patients they serve.
And now over to Preston.
Preston Wells, Stryker Corporation - VP of IR 
Thanks, Kevin. My comments today will focus on providing additional insight into the current environment and how certain countries and products performed during the quarter.
We saw progressive improvement in sales throughout the quarter, with April being the low point. The improving trends were primarily driven by the resumption of elective procedures. That momentum is continuing into Q3 as July is trending better than June. We estimate that approximately 40% to 50% of our total global revenue includes procedures that are considered elective or more accurately can be, in many cases, deferred for a period of time. This primarily includes hips and knees, extremities, spine, sports medicine and our ENT business. Geographically, elective procedure recovery varied depending on the government actions and severity of the pandemic.
In addition to the U.S., countries like China, Australia and Germany have also shown month-to-month improvements as elective procedures returned during the quarter, reaching approximately 85% to 90% of pre-COVID levels. The U.K., India and Latin America lagged during the quarter, at less than 50% of pre-COVID levels, as the pandemic continues to spread in these countries.
During the quarter, we saw strong demand for our large capital products, specifically beds and stretchers within our Medical division and ongoing high demand for our Mako robotic technology. In the second quarter, we were very pleased with the Mako installations in the U.S., including increased sales to ASCs and competitive accounts. We continue to see a growing percentage of both hip and knee replacement surgeries being performed with the Mako robot. As it relates to knees, there is an ongoing shift towards cementless. We also launched a new software upgrade for the Mako Hip program that includes features which improve the overall ease of use. Our leadership in orthopedic robotics, a strong order book, and a solid innovation pipeline positions us well to see continued above-market growth in joint replacement.
While we have made meaningful reductions in many discretionary spend items, our investment in R&D remains robust, as does our healthy cadence of new product introductions. During the first half of the year, we are pleased with the customer feedback and results from several new products, some of which include Spine's (inaudible) system, Mini Frag cleaning in Trauma and Neurovascular Vecta 71 and 74 intermediate catheters. These and other launches will contribute to our performance for the rest of the year and position us well for the future.
Although the COVID-19 pandemic has led to a slowdown in elective procedures, it has also placed increased emphasis on the safety of health care providers and their patients. Over the years, we have built an extensive portfolio within our MedSurg businesses, addressing many of the challenges our customers face, with a focus on accident and infection prevention and caregiver safety. This includes products like our patient hygiene and disinfecting products, personal protective equipment, waste management and smoke evacuation devices along with the LUCAS chest compression system which delivers high-quality automated CPR, while reducing the proximity of the caregiver to the patient.
With the ongoing threat of COVID-19 infections, the Department of Defense identified automated compression devices, such as the LUCAS device, as the best practice for delivery of CPR. Demand for these products grew during the quarter in response to these increased safety concerns. We will continue to leverage our diverse portfolio to address changing trends and meet the expectations of our customers, caregivers and patients.
With that, I will now turn the call over to Glenn.
Glenn S. Boehnlein, Stryker Corporation - VP & CFO 
Thanks, Preston. Today, I will focus my comments on our second quarter financial results, related drivers and liquidity matters. Our detailed financial results have been provided in today's press release.
Our organic sales decline was 24% in the quarter. These results included a decline in the U.S. of 24 -- 27.4% and an international decline of 14.5%. As a reminder, this quarter included the same number of selling days as compared to Q2 2019. Pricing in the quarter was unfavorable 0.2% from the prior year quarter, and foreign currency had an unfavorable 0.8% impact on sales. During the quarter, our growth was significantly negatively impacted by reductions in elective surgeries, the effects of shelter-in-place orders across many geographies and the pause in hospital capital spending as the medical community navigates this pandemic.
Throughout the quarter, we saw progressive improvement in the expansion of elective surgeries across many geographies which resulted in significant variability in our sales. On an overall basis, our sales decline ranged from minus 36% in April to minus 10% in June.
Our adjusted quarterly EPS of $0.64 represents a decline of 67.7% from Q2 2019. The foreign currency impact on second quarter EPS was minimal. Certain other factors resulted in disproportionately negative impacts on EPS, including the loss of higher-margin sales and a loss of leverage related to manufacturing and operational fixed costs. These were partially offset by our strong focus on disciplined cost control within the quarter.
I will now provide some brief comments on segment sales. Orthopaedics had constant currency and organic sales decline of 29.3%. This included a U.S. decline of 28.8%. We saw declines across our hip, knee and trauma businesses. We also saw very strong growth in our Mako business somewhat offset by declines in bone cement. Internationally, Orthopaedics had an organic decline of 30.4%, which reflects the downturn in elective procedures across most geographies.
MedSurg had constant currency decline of 16.4% and an organic sales decline of 17%, which included a 22.2% decline in the U.S.
Instruments had U.S. organic sales decline of 38%, driven by power tools, waste management and SurgiCount. This was partially offset by increases in Instruments' PPE products, namely our Flyte helmet and other protective products. As a reminder, Instruments also had a very high comparable in Q2 2019 with 19% growth.
Endoscopy had U.S. organic sales decline of 34.1%. This reflects a slowdown in its video, general surgery, communications and sports medicine businesses.
The Medical division had U.S. organic growth of 5.4%, reflecting strong demand across its bed and emergency care businesses, resulting from demand tied to COVID-19, which was offset by declines in Sage related to less patient flow.
Internationally, MedSurg had organic sales growth of 4.6%, reflecting strong demand for medical products in Australia, Canada, Europe and emerging markets.
Neurotechnology and Spine had a constant currency decline of 28.9% and an organic decline of 29.9%. Our U.S. Neurotech business posted a constant currency decline of 36.4% and a 37.5% organic decline for the quarter. This reflects a slowdown in procedures in the quarter related to all our Neurotech businesses. The decline was most pronounced in our ENT, neurosurgical and CMF businesses.
Internationally, neurotechnology and spine had an organic decline of 13%, reflecting slowdowns in Europe, Canada and emerging markets, which was offset by a solid performance in our neurovascular business.
Now I will discuss operating metrics in the quarter. Our adjusted gross margin of 57.3% was unfavorable 850 basis points from the prior year quarter. Compared to the prior year, gross margin was unfavorably impacted by fixed cost absorption and business mix. The fixed cost absorption was significant and related to certain costs associated with idle manufacturing that normally would be capitalized into inventory.
During Q2, we operated at 60% of normal capacity and the related unabsorbed costs diluted our margin by approximately 400 basis points. We anticipate Q3 will be at an average capacity of approximately 85%. Unabsorbed costs will continue to impact our margin until our manufacturing is operating at normal levels. Adjusted R&D spending was 7.6% of sales.
Our adjusted SG&A was 37.1% of sales, which was 360 basis points unfavorable to the prior year quarter. Compared to the prior year, SG&A was unfavorably impacted by business mix and deleveraging of selling and marketing costs, partially offset by operating expense savings actions taken during the quarter.
In summary, for the quarter, our adjusted operating margin was 12.5% of sales. The measures we enacted in March, covering most of our discretionary spending, including curtailments in hiring, travel, meetings and consulting as well as the idling of certain manufacturing lines and facilities, including furloughing the related workers continued throughout the second quarter.
Related to other income and expense as compared to prior year quarter, we saw a decline in investment income earned on deposits and interest expense increases related to increases in our debt outstanding. Our second quarter had an adjusted effective tax rate of 14.4%.
Originally posted here:
- Voice Biometrics Technology Market: Year 2021-2028 and its Detail Analysis by Focusing on Top Key Players like 3M Cogent, NEC Corporation of America,... - July 12th, 2021
- Facial Recognition System Market Will Generate Revenue, Opportunity and Huge Sales Near Future 2021-2027 The Manomet Current - The Manomet Current - July 12th, 2021
- Image Recognition AI Camera Market Business Strategies and Opportunities, Challenges with Top Trending Key Players || Catchoom, Honeywell... - July 12th, 2021
- JAMA Highlights Success of BrainScope's EEG-based Concussion Index As Reliable Indicator of Concussion - Herald-Mail Media - February 17th, 2021
- The benefits and risks of neural interfaces - Bangkok Post - February 17th, 2021
- Facial Recognition System Market to Witness Robust Expansion Throughout the Forecast Period 2018-2026 - The Daily Chronicle - October 3rd, 2020
- Neurotechnology Market Trends by Manufacturers, States, Type and Application, Forecast to 2020 2030 - The Daily Chronicle - September 8th, 2020
- Neurotech Bill Introduced in Both Senate and House of Representatives - Epilepsy Foundation - September 8th, 2020
- Global Neurotechnology Market Revenue to Witness Steady Growth Through 2025 - Industry Today - September 8th, 2020
- Facial Recognition Market Share, Size, Status, Manufactures, Growth and Forecast 2020-2025 - The Daily Chronicle - September 8th, 2020
- AI X-ray scanner and robotic muscles could be adopted by NHS - E&T Magazine - September 8th, 2020
- Stryker to participate in the Morgan Stanley 18th Annual Virtual Global Healthcare Conference - Yahoo Finance - September 8th, 2020
- Walk-through cancer diagnoses and robotics muscles among groundbreaking projects backed by government - GOV.UK - September 8th, 2020
- Stryker's AxSOS 3 Ankle Fusion System Offers Innovative Plates That Are Designed to Fit a Range of Patients - BioSpace - September 8th, 2020
- Arctop Launches New State-of-the-Art Brain Decoding Technology: Neuos Eureka - Business Wire - August 10th, 2020
- Global Projection 2020: Facial Recognition Market Exclusive Profitable Comprehensive Research Report with COVID-19 Impact Overview | Forecast 2029 -... - August 10th, 2020
- Neurolief Awarded Breakthrough Device Designation from FDA for Wearable Technology to Address Major Depression - Business Wire - August 10th, 2020
- Brave users of Elon Musks Neuralink brain implants could be HACKED by crooks in future, cyber-experts sugge - The Sun - August 10th, 2020
- Stryker's Neuroform Atlas Stent System granted an expanded indication - DOTmed HealthCare Business News - August 9th, 2020
- Impact of Covid-19 on 3D Reconstruction Technology Market has Huge Growth in Industry | Neurotechnology, Vi3dim, Phenom-World - Levee Report - August 8th, 2020
- Soon, your brain will be connected to a computer. Can we stop hackers breaking in? - ZDNet - August 8th, 2020
- Stryker's Neuroform Atlas Stent System granted an expanded indication, providing a new option for patients with aneurysms in the back of the brain -... - August 6th, 2020
- Demand for Facial Recognition Market to Experience a Significant Dip in 2020, Influenced by COVID-19 Pandemic 2020-2029 | Aware Inc, NEC Corporation -... - August 6th, 2020
- New #BlackInNeuro Campaign Connects Bright Minds From Around The World - Forbes - August 6th, 2020
- Indian School Of Media: 70 EMG Founder Martin Da Costa speaks about his journey and events in the post-covid age. - Animation Xpress - August 6th, 2020
- Face Recognition Market Research Report by Type, by Computing, by Vertical, by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19 -... - August 6th, 2020
- Stryker (SYK) Q2 Earnings and Revenues Surpass Estimates - Yahoo! Voices - August 3rd, 2020
- Top Shorts In The Last Eight Years That Paid Off Big Time - Yahoo Finance - August 3rd, 2020
- Stryker (SYK) to Report Q2 Earnings: What's in the Cards? - Yahoo Finance - August 3rd, 2020
- Life Lived On Screen: Philosophical, Poetic, and Political Observations - lareviewofbooks - August 3rd, 2020
- Facial Recognition Market 2020, Industry Overview by Current-Status, Advancements, Top Trends, Challenges, Investment, Strong Development and Forecast... - July 31st, 2020
- Artificial Intelligence Will Be Vastly Smarter Than Humans Within Five Years, Says Tech Billionaire Elon Musk - Swarajya - July 31st, 2020
- How Neurotechnology Market Will Dominate In Coming Years? Report Covering Products, Financial Information, Developments, Swot Analysis And Strategies... - July 30th, 2020
- MOBILE BIOMETRICS MARKET TRENDS, TECHNOLOGY AND FORECAST | BY TOP COMPANIES APPLE INC.; IDEMIA; NUANCE COMMUNICATIONS, INC.; NEC CORPORATION - Market... - July 30th, 2020
- Ti'Air Riggins: Prolonging the function of brain implants - MSUToday - July 30th, 2020
- Global Face and Voice Biometrics Market 2025 Real Time Analysis & Forecast of COVID 19 Impact on Top Manufacturers: 3M Cogent (USA), NEC... - July 30th, 2020
- Facial Recognition Market 2020 Size, Share Growth, Trend, Industry Analysis and Forecast to 2025 - Market Research Posts - July 30th, 2020
- Neurology Devices Market Outlook To 2026 - Business Opportunity and Technological Innovations - Market Research Posts - July 30th, 2020
- Facial Recognition Technology Market Global Production, Growth, Share, Demand and Applications Forecast to 2028 - Market Research Posts - July 29th, 2020
- Global Facial Recognition Software Market Report 2020 with Industry Positioning of Key Vendors & COVID-19 Impact Analysis : Cognitec Systems GmbH,... - July 29th, 2020
- Global Face and Voice Biometrics Market Projected to Reach USD XX.XX billion by 2025- 3M Cogent (USA), NEC Corporation of America (USA), AcSys... - July 29th, 2020
- Facial Recognition Market is Expected To Thrive At Impressive CAGR By 2025 NEC Corporation, Aware, Inc., Ayonix Corporation, Cognitec Systems GmbH,... - July 27th, 2020
- Facial Recognition Technology Market Current Trends, SWOT Analysis, Business Overview and Forecast by 2028 - Bulletin Line - July 27th, 2020
- Global Neurosurgery Market 2020 Expected to Reach Highest CAGR During COVID 19 crisis ,Share Growth, Trends, Devices, Applications, Competitive... - July 27th, 2020
- Global and Country Specific Neural Control Market Report 2020 Forecast, Opportunities and Strategies To 2027: COVID 19 Impact and Recovery Top Key... - July 26th, 2020
- NASA warns of a massive asteroid bigger than the famous London Eye approaching Earth on July 24 - Business Insider India - July 25th, 2020
- Neurotechnology Market Poised to Grow at a Healthy CAGR of XX% During the Forecast Period 2017 2025 - 3rd Watch News - July 22nd, 2020
- Fingerprint Biometrics In The VAR Market 2020 by Innovations, New Technology And Research- Fulcrum Biometrics, Neurotechnology, 360 Biometrics,... - July 22nd, 2020
- Facial Recognition Market 2025: Research By Top Manufacturers with Market Size,Market Growth, Competitive Regions with Opportunities in Industry -... - July 22nd, 2020
- Neurosurgery Market Growth, Analysis, Regions and Type by 2026 - 3rd Watch News - July 22nd, 2020
- I Am Therefore I Am Wrong - Dr. Howard Rankin on Recovery Now with Kim Justus - BlogTalkRadio - July 22nd, 2020
- Facial Recognition Market 2020 Size By Product Types, End-Users, Regional Outlook, Growth Potential, Price Trends And Forecast To 2025 - Cole of Duty - July 21st, 2020
- What is NeuroTechnology? | NeuroTechnology and Hearing Loss - July 21st, 2020
- Facial Recognition Market Outlook, Growth, Trends, Analysis And Forecast To 2020-2025 - Jewish Life News - July 21st, 2020
- 2020 to 2026 Global Face and Voice Biometrics Market Research Analysis Report with 3M Cogent (USA), NEC Corporation of America (USA), AcSys Biometrics... - July 21st, 2020
- COVID-19 Impact on Facial Recognition Market by Component (Software Tools and Services), Vertical (BFSI, Government & Defense, Retail &... - July 21st, 2020
- The FINANCIAL - Neuralink chip will stream music into your brain - The FINANCIAL - July 21st, 2020
- Facial Recognition System Market Analysis by Current Status & Target Audience and Forecast to 2027 - 3rd Watch News - July 19th, 2020
- Neurotechnology Market: Qualitative Analysis of the Leading Players and Competitive Industry Scenario, 2025 - Express Journal - July 16th, 2020
- Virtual Reality in Therapy Market 2020 2023: Company Profiles, COVID 19 Outbreak, Regional Study, Emerging Technologies, Business Trends, Industry... - July 16th, 2020
- Elon Musk to release progress update on Neuralink brain chip on August 28 - Inceptive Mind - July 13th, 2020
- Facial Recognition Technology Market Key Drivers, Business Insights, Trends And Forecast To 2028 - Jewish Life News - July 13th, 2020
- MOBILE BIOMETRICS MARKET TRENDS, TECHNOLOGY AND FORECAST | BY TOP COMPANIES APPLE INC.; IDEMIA; NUANCE COMMUNICATIONS, INC.; NEC CORPORATION - Jewish... - July 13th, 2020
- Clinicians find encouraging results from functional MR in an unresponsive patient with COVID-19 - DOTmed HealthCare Business News - July 13th, 2020
- Elon Musk says Neuralinks capability to cure mental illness is great and terrifying - Republic World - Republic World - July 11th, 2020
- Encouraging results from functional MRI in an unresponsive patient with COVID-19 - Science Codex - July 11th, 2020
- Facial Recognition System Market: Deep Analysis by Production Overview and Insights 2018 - Market Research Publicist - July 11th, 2020
- Humans 'prick' their ears up just like cats and dogs when they hear interesting sounds, scientists find - Telegraph.co.uk - July 11th, 2020
- Face Recognition Software Market Share, Growth, Statistics, By Application, Production, Revenue & Forecast To 2026 - Owned - July 11th, 2020
- Trending: Neurotechnology Market 2020- Analysis And In-Depth Research On Market Size, Trends, Emerging Growth Factors And Forecast To 2026 - Cole of... - June 21st, 2020
- Growth of Facial Recognition Technology Market has been derived from the growing CAGR 2020-2028 - WorldsTrend - June 21st, 2020
- Meet 10 Companies Working On Reading Your Thoughts (And Even Those Of Your Pets) - Forbes - June 21st, 2020
- Vagus Nerve Stimulation Breakthrough Suggests Route To Therapies for Arthritis, Heart Failure - Technology Networks - June 18th, 2020
- 2020 Judges, FAQ, and Nominations - MIT Technology Review - June 18th, 2020
- Impact of COVID-19 Outbreak on Global Face and Voice Biometrics Market 2020 Industry Size, Advancement Strategy, Top Players, SWOT Analysis and 2025... - June 18th, 2020
- Read Only Memories: Neurodiver Gets PS4, Xbox One, And PC Release Window - Noisy Pixel - June 18th, 2020
- Partnership brings together education and diagnostic tool on concussion - Med-Tech Innovation - May 19th, 2020
- Facial Recognition Market Report 2020 Industry Size, Share, Growth, Trends, Sales Revenue, Business Strategies, Key Countries Analysis by Leading... - May 19th, 2020
- Neurotechnology overview: Why we need a treaty to regulate weapons controlled by thinking - Bulletin of the Atomic Scientists - May 3rd, 2020
- NeuroOne Medical Technologies Corp. Appoints Vanessa Tolosa to Scientific Advisory Board: Leading Researcher in Neurotech to Guide Further Development... - May 3rd, 2020